<DOC>
	<DOC>NCT02024633</DOC>
	<brief_summary>Research Hypothesis: icotinib administered in combination with gemcitabine has an acceptable safety profile in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma.The primary objective is to determine the safety profile of icotinib in combination with gemcitabine in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma.</brief_summary>
	<brief_title>Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Locally advanced, unresectable or metastatic pancreatic cancer by histologic or cytologic confirmation without previous chemotherapy or target therapy. ECOG Performance Status of 0 to 1. Adequate organ function as defined by studyspecified laboratory tests. Signed informed consent form. Willing and able to comply with study procedures. Previous chemotherapy or target therapy. Currently have or have history of certain studyspecified heart, liver, kidney, lung, neurological, immune or other medical conditions. Systemically active steroids. Another investigational product within 28 days prior to receiving study drug. Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug. Infection with HIV, hepatitis B or C at screening. Pregnant or lactating. Conditions, including alcohol or drug dependence, or intercurrent illness that would affect the patient's ability to comply with study visits and procedures.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>